JAZZ up +1.78% percent Today $JAZZ High is at 172.
Post# of 76
Posted On: 11/18/2014 11:11:30 AM
JAZZ up +1.78% percent Today $JAZZ High is at 172.84 and the Low 168.36 with current volume of 171,396.
Recent News posted below.
Jazz Pharmaceuticals JAZZ other info.
http://investorshangout.com/Jazz-Pharmaceuticals-JAZZ-54526/
JAZZ Jazz Pharmaceuticals Recent Headline News
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 2.91% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 5:05PM CST
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $168.22 to a high of $177.36. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $170.58 on volume of 864,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 169.80 (+0.31)
Earnings Look Back: Jazz Pharmaceuticals Is Up 3.6% Since Reporting Quarterly Results 1 Week Ago (JAZZ)
Comtex SmarTrend(R) - Mon Nov 17, 4:12PM CST
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings a week ago on November 4th, 2014, analysts, on average, expected the company to report earnings of $2.23 on sales of $302.9 million. The company actually reported EPS of $2.33 on sales of $306.6 million, beating EPS estimates by $0.10 and beating revenue estimates by $3.6 million. Since the company's report, shares of Jazz Pharmaceuticals have risen from $168.48 to $174.57, representing a gain of 3.6% in the past 13 days.
JAZZ: 169.80 (+0.31)
Is Jazz Pharmaceuticals (JAZZ) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 8:03AM CST
Jazz Pharmaceuticals is one such company that might be well-positioned for future earnings growth as this firm, which is in the healthcare sector, saw EPS growth of 25.5% last year, and is looking great for this year too.
JAZZ: 169.80 (+0.31)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 169.80 (+0.31), ARQL: 1.22 (-0.02), SCMP: 12.00 (+0.41), RDY: 56.36 (+0.27)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 260.77 (+12.83), LUV: 39.40 (+0.33), IYZ: 30.61 (+0.03), SPY: 205.14 (+0.77), IDU: 114.56 (+0.39), AMAT: 22.60 (+0.12), JAZZ: 169.80 (+0.31), IYW: 104.47 (+0.45), FDX: 172.03 (+0.71), IYK: 104.66 (+0.21), IYJ: 106.81 (+0.50), XTN: 102.50 (+0.80), IYH: 143.67 (+1.82), LSTR: 75.61 (+0.16), SWKS: 62.95 (+0.80), IYM: 85.76 (+0.60), IYC: 130.60 (+0.02), NXPI: 74.76 (+0.39), SOXX: 88.48 (+1.01), IYF: 88.10 (+0.30), IYE: 48.53 (-0.04), ADM: 51.90 (-0.09), ARRS: 28.72 (+0.55), PJP: 67.36 (+0.85), ALXN: 190.14 (+3.36)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 69.41 (+2.35), ACT: 260.77 (+12.83), JAZZ: 169.80 (+0.31), UNH: 98.50 (+2.03), CELG: 106.62 (+2.26), CELGZ: 3.18 (-0.03)
Update: Jazz Pharmaceuticals Q3 Earnings
ONeil Trader - at Seeking Alpha - Fri Nov 07, 10:00AM CST
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences
PR Newswire - Thu Nov 06, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals (JAZZ) Downgraded From Buy to Hold
at The Street - Thu Nov 06, 8:21AM CST
Jazz Pharmaceuticals (JAZZ) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
JAZZ: 169.80 (+0.31)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 305.51 (+3.09), PCYC: 137.85 (+2.75), PSTI: 2.66 (-0.04), NBS: 5.27 (-1.51), ALDR: 16.89 (+0.03), IDRA: 2.42 (+0.04), SGEN: 37.74 (+1.89), JAZZ: 169.80 (+0.31), ALXN: 190.14 (+3.36), KMDA: 3.39 (+0.08), ATHX: 1.40 (+0.03), NVS: 95.45 (+1.07)
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 305.51 (+3.09), JAZZ: 169.80 (+0.31), AMAG: 35.91 (+1.15)
Stocks Open To Staggered Gains; Time Warner, NXP, Jazz Climb
at Investor's Business Daily - Wed Nov 05, 9:38AM CST
Stocks jumped off to modest gains in mixed trade early Wednesday. The S&P 500 led with a 0.4% advance. The Dow Jones industrial average climbed 0.3% and the Nasdaq added 0.1%. Volume rose 20% on the Nasdaq and dipped 4% on the NYSE. The stock market...
JAZZ: 169.80 (+0.31), TRIP: 69.90 (+1.37), NXPI: 74.76 (+0.39), TMH: 55.66 (+0.83), TWX: 80.20 (-0.20)
Jazz Pharmaceuticals Public (JAZZ) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 7:50AM CST
The following Jazz Pharmaceuticals Public (JAZZ) conference call took place on November 4, 2014, 04:30 PM ET. This is a transcript of that earnings call:
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals Public Limited's (JAZZ) CEO Bruce Cozadd on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:20PM CST
JAZZ: 169.80 (+0.31)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 212.07 (+2.87), BIIB: 305.51 (+3.09), VRX: 141.44 (+4.71), ACT: 260.74 (+12.80), JAZZ: 169.80 (+0.31), ALXN: 190.14 (+3.36), CELG: 106.62 (+2.26)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 51.50 (+2.72), MNST: 109.86 (-0.21), SWKS: 62.95 (+0.80), GMCR: 158.03 (+3.53), ILMN: 190.42 (+7.51), WSM: 69.44 (-0.16), NXPI: 74.76 (+0.39), CELG: 106.62 (+2.26), HAIN: 107.84 (-0.57), AGN: 212.07 (+2.87), CNC: 98.77 (+0.75), V: 249.95 (+0.15), CALM: 42.48 (+0.31), JAZZ: 169.80 (+0.31), ALXN: 190.14 (+3.36), LOW: 58.23 (-0.66), ULTA: 124.35 (+0.15), MA: 83.56 (+0.36), AVGO: 89.27 (+0.75), PETM: 72.89 (-0.72)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 258.34 (+4.36), ACT: 260.74 (+12.80), FEYE: 32.08 (-0.24), AWAY: 30.23 (-0.11), CYBR: 42.31 (-1.14), JAZZ: 169.80 (+0.31), TRIP: 69.90 (+1.37), PANW: 110.01 (+0.66), ATHM: 41.71 (-1.14)
Jazz Pharmaceuticals beats by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:22PM CST
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance
PR Newswire - Tue Nov 04, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2014 and updated financial guidance for full year 2014.
JAZZ: 169.80 (+0.31)
Stocks Turn Mixed; Epam Bounces Back
at Investor's Business Daily - Tue Nov 04, 2:13PM CST
Stocks continued to improve late Tuesday, turning mixed. The Dow Jones industrial average bounced back from a 0.5% loss and was up a fraction. The broader Nasdaq and the S&P 500 were off 0.4% each. They had been off 0.9% and 0.8%, respectively. NYSE...
FEYE: 32.08 (-0.24), AWAY: 30.23 (-0.11), FRGI: 56.56 (+0.90), SAVE: 76.00 (+0.89), LNKD: 225.29 (+2.01), SCTY: 56.29 (+2.70), STE: 63.57 (+0.30), PZZA: 49.16 (+0.20), JAZZ: 169.80 (+0.31), FL: 54.73 (-0.07), EPAM: 49.27 (-0.42)
Recent News posted below.
Jazz Pharmaceuticals JAZZ other info.
http://investorshangout.com/Jazz-Pharmaceuticals-JAZZ-54526/
JAZZ Jazz Pharmaceuticals Recent Headline News
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 2.91% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 5:05PM CST
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $168.22 to a high of $177.36. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $170.58 on volume of 864,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 169.80 (+0.31)
Earnings Look Back: Jazz Pharmaceuticals Is Up 3.6% Since Reporting Quarterly Results 1 Week Ago (JAZZ)
Comtex SmarTrend(R) - Mon Nov 17, 4:12PM CST
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings a week ago on November 4th, 2014, analysts, on average, expected the company to report earnings of $2.23 on sales of $302.9 million. The company actually reported EPS of $2.33 on sales of $306.6 million, beating EPS estimates by $0.10 and beating revenue estimates by $3.6 million. Since the company's report, shares of Jazz Pharmaceuticals have risen from $168.48 to $174.57, representing a gain of 3.6% in the past 13 days.
JAZZ: 169.80 (+0.31)
Is Jazz Pharmaceuticals (JAZZ) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 8:03AM CST
Jazz Pharmaceuticals is one such company that might be well-positioned for future earnings growth as this firm, which is in the healthcare sector, saw EPS growth of 25.5% last year, and is looking great for this year too.
JAZZ: 169.80 (+0.31)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 169.80 (+0.31), ARQL: 1.22 (-0.02), SCMP: 12.00 (+0.41), RDY: 56.36 (+0.27)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 260.77 (+12.83), LUV: 39.40 (+0.33), IYZ: 30.61 (+0.03), SPY: 205.14 (+0.77), IDU: 114.56 (+0.39), AMAT: 22.60 (+0.12), JAZZ: 169.80 (+0.31), IYW: 104.47 (+0.45), FDX: 172.03 (+0.71), IYK: 104.66 (+0.21), IYJ: 106.81 (+0.50), XTN: 102.50 (+0.80), IYH: 143.67 (+1.82), LSTR: 75.61 (+0.16), SWKS: 62.95 (+0.80), IYM: 85.76 (+0.60), IYC: 130.60 (+0.02), NXPI: 74.76 (+0.39), SOXX: 88.48 (+1.01), IYF: 88.10 (+0.30), IYE: 48.53 (-0.04), ADM: 51.90 (-0.09), ARRS: 28.72 (+0.55), PJP: 67.36 (+0.85), ALXN: 190.14 (+3.36)
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 69.41 (+2.35), ACT: 260.77 (+12.83), JAZZ: 169.80 (+0.31), UNH: 98.50 (+2.03), CELG: 106.62 (+2.26), CELGZ: 3.18 (-0.03)
Update: Jazz Pharmaceuticals Q3 Earnings
ONeil Trader - at Seeking Alpha - Fri Nov 07, 10:00AM CST
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences
PR Newswire - Thu Nov 06, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals (JAZZ) Downgraded From Buy to Hold
at The Street - Thu Nov 06, 8:21AM CST
Jazz Pharmaceuticals (JAZZ) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
JAZZ: 169.80 (+0.31)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 305.51 (+3.09), PCYC: 137.85 (+2.75), PSTI: 2.66 (-0.04), NBS: 5.27 (-1.51), ALDR: 16.89 (+0.03), IDRA: 2.42 (+0.04), SGEN: 37.74 (+1.89), JAZZ: 169.80 (+0.31), ALXN: 190.14 (+3.36), KMDA: 3.39 (+0.08), ATHX: 1.40 (+0.03), NVS: 95.45 (+1.07)
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 305.51 (+3.09), JAZZ: 169.80 (+0.31), AMAG: 35.91 (+1.15)
Stocks Open To Staggered Gains; Time Warner, NXP, Jazz Climb
at Investor's Business Daily - Wed Nov 05, 9:38AM CST
Stocks jumped off to modest gains in mixed trade early Wednesday. The S&P 500 led with a 0.4% advance. The Dow Jones industrial average climbed 0.3% and the Nasdaq added 0.1%. Volume rose 20% on the Nasdaq and dipped 4% on the NYSE. The stock market...
JAZZ: 169.80 (+0.31), TRIP: 69.90 (+1.37), NXPI: 74.76 (+0.39), TMH: 55.66 (+0.83), TWX: 80.20 (-0.20)
Jazz Pharmaceuticals Public (JAZZ) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 7:50AM CST
The following Jazz Pharmaceuticals Public (JAZZ) conference call took place on November 4, 2014, 04:30 PM ET. This is a transcript of that earnings call:
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals Public Limited's (JAZZ) CEO Bruce Cozadd on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 7:20PM CST
JAZZ: 169.80 (+0.31)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 212.07 (+2.87), BIIB: 305.51 (+3.09), VRX: 141.44 (+4.71), ACT: 260.74 (+12.80), JAZZ: 169.80 (+0.31), ALXN: 190.14 (+3.36), CELG: 106.62 (+2.26)
Top Funds Buy Ulta Beauty, Alexion, Avago
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Managers of leading mutual funds in recent months have continued to stock up on large medical stocks, such as Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Celgene (CELG), Jazz Pharmaceuticals (JAZZ),Allergan (AGN) and Centene (CNC). The...
AMBA: 51.50 (+2.72), MNST: 109.86 (-0.21), SWKS: 62.95 (+0.80), GMCR: 158.03 (+3.53), ILMN: 190.42 (+7.51), WSM: 69.44 (-0.16), NXPI: 74.76 (+0.39), CELG: 106.62 (+2.26), HAIN: 107.84 (-0.57), AGN: 212.07 (+2.87), CNC: 98.77 (+0.75), V: 249.95 (+0.15), CALM: 42.48 (+0.31), JAZZ: 169.80 (+0.31), ALXN: 190.14 (+3.36), LOW: 58.23 (-0.66), ULTA: 124.35 (+0.15), MA: 83.56 (+0.36), AVGO: 89.27 (+0.75), PETM: 72.89 (-0.72)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 258.34 (+4.36), ACT: 260.74 (+12.80), FEYE: 32.08 (-0.24), AWAY: 30.23 (-0.11), CYBR: 42.31 (-1.14), JAZZ: 169.80 (+0.31), TRIP: 69.90 (+1.37), PANW: 110.01 (+0.66), ATHM: 41.71 (-1.14)
Jazz Pharmaceuticals beats by $0.11, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:22PM CST
JAZZ: 169.80 (+0.31)
Jazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance
PR Newswire - Tue Nov 04, 3:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2014 and updated financial guidance for full year 2014.
JAZZ: 169.80 (+0.31)
Stocks Turn Mixed; Epam Bounces Back
at Investor's Business Daily - Tue Nov 04, 2:13PM CST
Stocks continued to improve late Tuesday, turning mixed. The Dow Jones industrial average bounced back from a 0.5% loss and was up a fraction. The broader Nasdaq and the S&P 500 were off 0.4% each. They had been off 0.9% and 0.8%, respectively. NYSE...
FEYE: 32.08 (-0.24), AWAY: 30.23 (-0.11), FRGI: 56.56 (+0.90), SAVE: 76.00 (+0.89), LNKD: 225.29 (+2.01), SCTY: 56.29 (+2.70), STE: 63.57 (+0.30), PZZA: 49.16 (+0.20), JAZZ: 169.80 (+0.31), FL: 54.73 (-0.07), EPAM: 49.27 (-0.42)
(0)
(0)Jazz Pharmaceuticals (JAZZ) Stock Research Links
Scroll down for more posts ▼